• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Exelixis adds top personnel

Exelixis adds top personnel

September 28, 2015
CenterWatch Staff

Exelixis has announced three high-level appointments as the company prepares for the potential commercialization of its lead compound, cabozantinib, for the treatment of advanced renal cell carcinoma (RCC) following positive results from the METEOR pivotal phase III trial. William Berg, M.D., has joined the company as senior vice president of medical affairs, Jonathan Berndt as vice president of sales, and Gregg Bernier as vice president of marketing.

“Exelixis is moving rapidly to thoughtfully expand our medical affairs and commercial capabilities in advance of our planned U.S. and E.U. regulatory filings for cabozantinib in advanced renal cell carcinoma in late 2015 and early 2016, respectively,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis.

Berg will oversee medical affairs in the U.S. He joins Exelixis after spending more than 12 years at Novartis, where he served in roles of increasing responsibility, including vice president and franchise head within global medical affairs. Before entering the pharmaceutical industry, Berg served on the faculty of the Memorial Sloan-Kettering Cancer Center.

Berndt will lead all sales activities for cabozantinib and also direct U.S. co-promotion efforts for cobimetinib, including Exelixis’ plans to field up to 25% of the cobimetinib U.S. sales force in the event of a potential regulatory approval later this year. Berndt joins Exelixis with two decades of commercial sales experience in the biopharmaceutical industry. Most recently, he served as senior director, oncology sales at Gilead Sciences. Previously, Berndt worked at Genentech for 13 years.

Bernier will lead the marketing group in its commercialization of cabozantinib for RCC. Bernier has more than 20 years of experience in biotech and pharmaceutical sales and marketing, primarily in oncology. Prior to joining Exelixis, he was senior director of marketing at Medivation. Bernier joined Medivation from Genentech, where he worked on a variety of product launches.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing